Misregulation of the canonical Wnt/b-catenin pathway and aberrant activation of Wnt signaling target genes are common in colorectal cancer (CRC) and contribute to cancer progression. Altered expression of human enhancer of filamentation 1 (HEF1; also known as NEDD9 or Cas-L) has been implicated in progression of melanoma, breast, and CRC. However, the regulation of HEF1 and the role of HEF1 in CRC tumorigenesis are not fully understood. We here identify HEF1 as a novel Wnt signaling target. The expression of HEF1 was upregulated by Wnt-3a, b-catenin, and Dvl2 in a dose-dependent manner, and was suppressed following b-catenin downregulation by shRNA. In addition, elevated HEF1 mRNA and protein levels were observed in CRC cell lines and primary tumor tissues, as well as in the colon and adenoma polyps of Apc Min/þ mice. Moreover, HEF1 levels in human colorectal tumor tissues increased with the tumor grade. Chromatin immunoprecipitation (ChIP) assays and promoter analyses revealed three functional T-cell factor (TCF)-binding sites in the promoter of HEF1 responsible for HEF1 induction by Wnt signaling. Ectopic expression of HEF1 increased cell proliferation and colony formation, while downregulation of HEF1 in SW480 cells by shRNA had the opposite effects and inhibited the xenograft tumor growth. Furthermore, overexpression of HEF1 in SW480 cells promoted cell migration and invasion. Together, our results determined a novel role of HEF1 as a mediator of the canonical Wnt/b-catenin signaling pathway for cell proliferation, migration, and tumorigenesis, as well as an important player in colorectal tumorigenesis and progression. HEF1 may represent an attractive candidate for drug targeting in CRC.
Introduction
Aberrant activation of Wnt signaling, arising from genetic defects in the tumor suppressor genes APC or AXIN1/2 or activating mutations in b-catenin, has been associated with the initiation of numerous types of cancer, and is common in colorectal cancer (CRC) (Morin et al., 1997; Liu et al., 2000; Satoh et al., 2000; Barker and Clevers, 2006; Segditsas and Tomlinson, 2006) . A primary consequence of Wnt signaling activation is the stabilization of b-catenin in the cytoplasm, resulting in an increased translocation of b-catenin to the nucleus. Nuclear b-catenin forms a complex with the TCF/LEF transcription factor leading to activation of Wnt target gene expression (Behrens et al., 1996; Novak and Dedhar, 1999) . To date, a variety of Wnt target genes, including the oncogenes c-Myc, cyclin D1, and Snail, have been identified and shown to play crucial roles in neoplastic transformation and cancer progression (He et al., 1998; Tetsu and McCormick, 1999; Zhai et al., 2002; Yook et al., 2006) . However, these are likely not the only critical Wnt targets in cancer development. Identification of additional important effectors will nominate new candidates for creation of targeted therapies useful for CRC management.
Human enhancer of filamentation 1 (HEF1), also known as NEDD9 or Cas-L, is a multi-domain scaffolding protein of the Cas family, which also includes p130Cas/BCAR1, HEPL, and Sin/Efs (O'Neill et al., 2000) . Similar to its family members, HEF1 localizes to focal adhesions to coordinate FAK and Src signaling cascades in integrin-dependent adhesion, migration, invasion, and survival (van Seventer et al., 2001; Natarajan et al., 2006) . High levels of HEF1 have been reported in various human cancers including melanoma and lung cancer, while deletion of HEF1 limited the growth of mammary tumors in MMTVpolyoma virus T antigen mice Ji et al., 2007; Izumchenko et al., 2009 ). HEF1 activity has been shown to be required for invasive behavior of glioblastomas (Natarajan et al., 2006) , metastasis of melanoma , and lung cancer (Ji et al., 2007) . A recent study provides in vivo evidence that HEF1 supports the activation of oncogenic signaling pathways including AKT, ERK, and SRC in breast cancer development (Izumchenko et al., 2009) . To date, no mutation affecting HEF1 function has been reported.
Transcriptional upregulation of HEF1 appears to be an important mechanism for its induction during cancer progression and metastasis. One report has observed high levels of HEF1 mRNA in ovarian cancer compared with normal ovarian epithelium (Donninger et al., 2004) . In research into transcriptional activation of HEF1, it has been shown that TGF-b treatment induces HEF1 partially through transcription (Zheng and McKeown-Longo, 2002) , retinoic acid induces HEF1 transcription in neuroblastoma cell lines (Merrill et al., 2004) , and progesterone receptor overexpression can induce upregulation of HEF1 mRNA in breast cancer cells (Richer et al., 2002) . Moreover, a genome-scale location analysis of binding sites for transcription factors associated with stem cells has shown that SOX2 and NANOG co-occupy the HEF1/NEDD9/ Cas-L promoter, suggesting the possible role of signaling pathways relevant to stem cell identity (Boyer et al., 2005) . However, the mechanism for the transcriptional regulation of HEF1 is not well understood, and few transcription factors directly regulating HEF1 expression have been identified for any tumor type.
In a systematic search for Wnt target genes by a bioinformatics-based analysis of predicted promoter regions within the human genome, we identified four consensus TCF-binding sites in the HEF1 promoter, suggesting HEF1 as a potential Wnt transcriptional target gene (Easwaran et al., 2003) . In this study, we investigated the transcriptional regulation of HEF1 and its role in colorectal tumorigenesis. These studies establish a clear link between the elevation of HEF1 expression in clinical samples, activation of Wnt signaling, and HEF1-dependent cell proliferation in CRC, implying that HEF1-specific interventions should be considered during the treatment of CRC.
Results

HEF1 is upregulated in CRC
To explore the role of HEF1 in CRC tumorigenesis, we first performed western blot analyses of 10 CRC and two normal colon epithelial cell lines. All CRC cell lines showed higher levels of HEF1 than the two normal cell lines (Figure 1a) . Quantification of the western bands indicated that on average, HEF1 levels were at least twofold higher (ranged from twofold to eightfold) in CRC cell lines than that in the normal colon cell lines (Po0.05; Supplementary Figure 1) . Immunofluorescence analysis of HEF1 also detected a more prominent signal in CRC versus normal colon cell lines (Figure 1b, upper panel) , with the most prominent staining located at focal adhesions as previously reported (Law et al., 2000) . Immunohistochemical analysis of three primary human CRC tumor specimens also revealed a higher level of HEF1 in tumor tissues than in matched adjacent normal tissues (Figure 1b, lower panel) . To determine whether the higher levels of HEF1 detected in CRC specimens was due to regulation at the mRNA level, we examined HEF1 mRNA levels in 14 pairs of human CRC tumor tissues and matched adjacent normal colon tissues by quantitative RT-PCR. The results demonstrated that 12 of 14 patients had elevated HEF1 mRNA level in CRC tumor tissues than in adjacent normal tissues, with an average of twofold increase (Po0.05; Figure 1c ). Similar results were obtained from analysis of an additional 40 RNA samples isolated from 36 CRC and 4 normal colonic tissues with statistically significant P-value (Po0.01; Figure 1d ). Collectively, these data suggested that the HEF1 is elevated in CRC at the transcriptional level.
HEF1 is a direct target of TCF/b-catenin signaling The majority of the CRC cell lines analyzed above carry mutations in the Wnt signaling pathway genes APC, b-catenin, or AXIN2 (Supplementary Table 1 Figure 2) . Reciprocally, shRNA knockdown of b-catenin in SW480 CRC cells significantly reduced HEF1 in both protein and mRNA level (Figures 2b and c) .
To further determine whether elevation of HEF1 occurs following activation of Wnt signaling in vivo, we analyzed HEF1 protein levels in small intestine and colon tissues from Apc Min/þ mice. The Apc Min/þ mouse harbors a premature stop codon at amino acid 850 of Apc, which results in hyperactivation of this Wnt effector (Velmurugan et al., 2010) . HEF1 expression was increased in the small intestine and colon as well as in adenoma polyps of Apc Min/þ mice as compared with colon tissues from wild-type mice (Figure 2d) . Similarly, immunohistochemical staining showed elevation of HEF1 and b-catenin in the small intestine and adenoma polyps of Apc Min/þ mice compared with that in the small intestine of C57Bl/6 control mice (Figure 2e) .
The direct activation of Wnt signaling target genes by the TCF/b-catenin transcription factors requires the presence of TCF-binding site(s) in the promoter of targeting gene (Behrens et al., 1996) . We analyzed the human HEF1 promoter in silico and found at least four consensus TCF/lymphoid enhancer family binding sites (5 0 -CTTTGNN-3 0 , wherein N is A or T) within 1.8 kb upstream of the transcriptional start site (Figure 3a) . These four predicted TCF-binding sites are conserved between human and rat (data not shown). We performed chromatin immunoprecipitation (ChIP) assays of the four TCF-binding sites using TCF4 or b-catenin-targeting monoclonal antibody, and IgG as a negative antibody control. Site 1 was pulled down efficiently by b-catenin-targeting monoclonal antibody but not by TCF-targeting monoclonal antibody, while sites 2-4 were pulled down by both antibodies (Figure 3b) .
We next cloned the HEF1 promoter (À2011 to þ 72) into the pGL3 Luciferase reporter vector, and generated five mutant constructs ablating the TCF-binding sites individually or in combination by site-directed mutagenesis (Figure 3c ). Co-expression of Dvl2 or b-catenin dramatically induced the activity of the wild-type HEF1 promoter-driven luciferase reporter (Figure 3c ). However, mutations at TCF sites 2, 3, or 4 in the HEF1 promoter significantly blocked the Dvl2 or b-catenininduced HEF1 promoter activation. Activity was almost completely lost when all sites were mutated (Po0.05 for all as compared with wild type; Figure 3c ). Data presented in Figures 3b and c complement one another nicely with respect to consensus sequence 1. These data demonstrated that HEF1 is a direct transcriptional target of TCF/b-catenin signaling. Take together, these data provide in vitro and in vivo evidence that the HEF1 promoter is activated in parallel with activation of the Wnt/b-catenin signaling pathway, and hence a direct Wnt signaling target.
HEF1 promotes cell proliferation and is upregulated during CRC progression Next, we investigated whether HEF1 positively regulates CRC tumorigenesis using cell proliferation assays and soft-agar colony formation analysis. Lentiviral transduction of HEF1-targeted shRNA into SW480 CRC cells typically reduced the normally high level of HEF1 expression by 90%. HEF1 downregulation reduced the anchorage-dependent growth rate of these cells more than sixfold and caused significant reduction of colony formation in soft agar relative to control (lentiviral vector)-transduced cells (Figure 4a ). Conversely, ectopic overexpression of HEF1 in the low-HEF1-expressing HEK293 cells increased cell proliferation rate by fivefold, and enhanced the formation of soft agar colonies ( Figure 4b ). These data indicate that HEF1 supports anchorage-independent cell growth, a key cancer-associated phenotype, implying that elevated HEF1 expression may predict more aggressive clinical manifestations of CRC. 
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To further assess the effect of HEF1 on tumor cell growth in vivo, we inoculated athymic nude (nu/nu) mice with SW480 CRC cells expressing a lentiviral vector in the left hind flank and a HEF1-specific lentiviral shRNA in the right flank. Consistent with the in vitro cell proliferation and colony formation observations, SW480 cells infected with HEF1-specific shRNA did not induce xenograft tumor growth after 5 weeks of s.c. inoculation while control SW480 cells, which express high level of HEF1, induced tumors in all mice (Figures 1a and 4c) . No evidence of metastasis to lymph nodes or other organs were observed in the shRNA control mice. Together, these xenograft tumor growth data suggest that HEF1 is essentially important for tumor growth in vivo.
To test whether changes in HEF1 expression were characteristic of a specific subset of human primary colorectal tumors, we performed immunohistochemical analysis of HEF1 protein expression in CRC tissue arrays. A total of 242 tissue cores were scored for HEF1 expression Among these arrays, 37 of 40 (93%) normal colonic tissues showed weak or no staining (0-1 þ ). In contrast, 21 of 28 (75%) well-differentiated CRC tissues showed moderate (2 þ ) staining, 65 of 111 (59%) and 41 of 111 (37%) moderately differentiated CRC showed moderate or strong staining (3 þ ), respectively, and 13 of 29 (45%) and 14 of 29 (48%) poorly differentiated CRC tissues were moderately or strongly stained (Table 1 ; Supplementary  Figure 3 ). These data clearly indicated that HEF1 expression is specifically associated with advanced CRC tumor grade, again implying that increased HEF1 expression is a relevant contributor to human CRC progression. HEF1 promotes colorectal tumorigenesis and progression Y Li et al HEF1 induces cell migration and metastasis of CRC Overexpression of HEF1 has been implicated in promoting cell migration and metastasis in various types of cancer including lung, breast, melanoma, and glioblastoma (Fashena et al., 2002; Kim et al., 2006; Natarajan et al., 2006; Ji et al., 2007) . To determine the role of HEF1 in CRC metastasis, we assessed the effects of HEF1 manipulation on cell migration and invasion. Overexpression of EGFP-HEF1 in HEK293 cells, which express low level of endogenous HEF1 increased cell migration capability more than fivefold compared with EGFP-expressing control cells (Figure 5a ). In contrast, HEF1-specific shRNA specifically reduced the rates of migration of SW480 or HeLa cells (Figure 5b ; Supplementary Figure 4 ). In addition, the invasion capability of the SW480 cells was reduced when HEF1 was knocked down compared with the control SW480 cells (Figure 5c ). To assess the in vivo correlation of HEF1 expression with metastasis, we further examined the expression of HEF1 in 34 lymph nodes from CRC patients by immunohistochemistry analysis. Although it is clear that the level of HEF1 is gradually increased in CRC from I-Meta to III-Meta (well differentiated to poorly differentiated CRC with metastasis), only 29% (10/34) of metastatic CRC tumors show the highest (3 þ ) HEF1 level, compared with 48% (14/29) of the poorly differentiated CRC tumors (Tables 1 and 2 ). One possible explanation for these data is that HEF1 may not directly or solely govern CRC metastasis to lymph nodes; other factors such as E-cadherin and dysadherin may be also required for the metastasis process in CRC (Batistatou et al., 2006) .
Discussion
In the current study, we demonstrated for the first time that elevated expression of HEF1 in CRC is due to direct binding of the TCF/b-catenin regulatory complex to the HEF1 promoter, and established that HEF1 is a novel Wnt signaling target gene. This conclusion is supported by the following evidence: (1) High levels of HEF1 mRNA and protein were observed in human CRC cell lines, in primary tumor tissue, and in Elevated expression of HEF1 has been shown to promote cancer progression and invasion in many cancer types including melanoma and breast cancer (Izumchenko et al., 2009) . In this study, we observed elevated expression of HEF1 in 10/10 of CRC cell lines (Tables 1 and 2 ). This could be due to two reasons. One is that the metastatic tissues analyzed in the tissue array were from patient lymph nodes. Metastasis into the lymph node may not require HEF1 since we observed that the HEF1 level is higher in the primary cell line SW480 than in a closely related lymph node metastatic cell line, SW620, derived from the same CRC patient (Figure 1a) . Analysis of tissues from other remote metastatic organs such as liver might produce different results. The other possible reason is that additional molecules such as PRL-3, S100A4, and BAMBI may be required for HEF1 to promote CRC metastasis (Fritzmann et al., 2009) . Further investigations are required to examine these two hypotheses. The HEF1 transcript has been reported to be upregulated by TGF-b, all-trans retinoic acid, or progesterone receptor A (Richer et al., 2002; Zheng and McKeown-Longo, 2002; Merrill et al., 2004) . However, the direct mechanisms by which HEF1 upregulation occurs following activation of these signaling pathways are unclear. Our identification of HEF1 as a Wnt signaling target provides a new avenue for understanding why HEF1 can be induced by these regulators, even in tumor types in which the upstream elements of the Wnt signaling pathway is not commonly activated. For example, it has been reported that TGF-b and Wnt signaling cross-regulate signaling processes during development based on common interaction with Smads (Letamendia et al., 2001) . Smads physically interact with TCF to regulate TCF target genes either independently or cooperatively (Labbe et al., 2000) . Potentially, TGF-b-dependent induction of HEF1 expression could be regulated by TGF-b-Smads-TCF/ b-catenin signaling.
The induction of HEF1 by all-trans retinoic acid or progesterone receptors could also be regulated through Wnt signaling. Although Wnt/b-catenin signaling could be positively or negatively affected by retinoic acid, recently reported that retinoic acid activated Wnt/bcatenin signaling at Wnt cell surface receptor level in mouse epiphyseal chondrocytes (Easwaran et al., 1999; Liu et al., 2002; Lu et al., 2005; Yasuhara et al., 2009) . Progesterone receptors can directly upregulate Wnt-1 to induce Wnt signaling activation in breast cancer (Faivre and Lange, 2007) . Interestingly, Xia et al. (2010) have very recently reported the regulation of HEF1 by prostaglandin E(2)[PGE(2)] in CRC, and indicated that HEF1 is a crucial downstream mediator of PGE (2) action during colorectal carcinogenesis. However, the mechanism of HEF1 activation by PGE(2) was not fully elucidated. Identification of HEF1 as a direct target of TCF/b-catenin in our study provides a clue that PGE(2) may also activate HEF1 through TCF signaling, since a link between PGE(2) and TCF was previously hypothesized (Fujino et al., 2002; Shao et al., 2005) . In future, unraveling the mechanisms of transcriptional regulation of HEF1 in the context of an expanded view of Wnt signaling pathway may suggest new approaches to the treatment of colorectal and other human cancers.
In conclusion, our results provide evidence that HEF1 is a novel TCF/b-catenin target gene that is upregulated in human CRC. The elevation of HEF1 in CRC is associated with cell proliferation and tightly correlated with cancer progression through promoting colonic cell migration. New therapeutic strategies aimed at disrupting this regulation or the function of the HEF1 protein may be of particular value for prevention of CRC progression.
Materials and methods
Cell lines, colon tissues, and reagents Human colon cancer cell lines (HT29, SNU-1047, Caco2, DLD-1, COLO-205, LST174T, CO115, LoVo, SW480, and HCT115), normal colonic epithelial cell lines (CRL-1807, CRL-1831), HeLa and HEK293 cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). Cancer cell lines were maintained in Dulbecco's modified Eagles medium, with 10% fetal bovine serum, and antibiotic-antimycotic (GIBCO Laboratories, Grand Island, NY, USA). Normal colonic epithelial cell line was maintained in Dulbecco's modified Eagles medium with 5% horse serum, 10 mg/ml insulin, 10 ng/ml EGF, 0.5 ng/ml hydrocortisone, and 100 ng/ml cholera toxin. Three pairs of CRC and matched adjacent normal tissues were collected at Mayo Clinic as previously described (Liu et al., 2000) . Recombinant human Wnt-3a and Wnt-5a were purchased from R&D systems (Minneapolis, MN, USA). Antibodies to b-catenin (BD Biosciences, San Jose, CA, USA), HEF1 (2G9) (IQ297, ImmuQuest, Cleveland, UK, USA), and b-actin (Sigma, St Louis, MO, USA) were used for western blotting and Abbreviations: HEF1, human enhancer of filamentation 1; IHC, immunohistochemistry.
The grades I-III in pathology diagnosis in equivalent to welldifferentiated, moderately differentiated, or poorly differentiated, respectively, under microscope.
HEF1 promotes colorectal tumorigenesis and progression Y Li et al immunostaining. Antibodies used for ChIP analysis were chip-grade TCF4 from CST (Danvers, MA, USA), b-catenin, and isotype IgG from Upstate Biotechnology (Lake Placid, NY, USA).
Mice and tissue sampling C57BL/6 and Apc Min/þ mice (on C57BL/6 background) aged at 6-8 weeks were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). All mice were housed in specific pathogen-free environment ad libitum access to food and water. Mice were allowed to grow until they were 4 months old and were killed by CO 2 asphyxiation. After the kill, the colon and small intestine were immediately removed and flushed with ice-cold saline to remove debris, then opened longitudinally. Tissues from five mice were snap frozen in liquid nitrogen and then stored in À80 1C for isolating protein, DNA, or RNA samples. Tissues from another five mice were fixed in 10% neutral buffered formaldehyde and then subjected to standard histological preparation for H&E staining and immunostaining. All procedures follow an animal use protocol approved by the Institutional Animal Care and Use Committee of Louisiana State University Health Sciences Center New Orleans.
Western blotting, immunofluorescence, and immunohistochemistry
Western blotting was performed as described previously , using 20 mg of total protein from each tissue or cell lysate. Proteins were visualized using an enhanced chemiluminescence kit (Thermo Scientific, Rockford, IL, USA). Immunofluorescence was performed using standard approaches, with cells stained with IQ297 (ImmuQuest) to visualize HEF1 and DAPI (Invitrogen, Carlsbad, CA, USA) to visualize nuclei. Imaging was performed using a Carl Zeiss Min/þ , and small intestines from control mice were deparaffinized, rehydrated, and then treated in 3% hydrogen peroxide in methanol to remove endogenous peroxidase. For the antigen retrieval, sections were boiled in 10 mM citric acid buffer (pH 6.0) at 100 1C for 20 min. HEF1 antibody was diluted at 1:100 in PBS-3% goat serum and followed by incubation with biotinylated goat anti-mouse antisera (Jackson ImmunoResearch Laboratory, West Grove, PA, USA) diluted 1:500 in PBS for 30 min at room temperature, and then followed according to the manufacturer's protocol of the Vectastain ABC immunodection kit (Vector Laboratories, Burlingame, CA, USA). Sections were counterstained with Harris hematoxylin solution (Sigma) and passed through a dehydration process, followed by coverslipping and mounting by using Cytoseal XYL (Richard Allan Scientific, Kalamazoo, MI, USA). The immunostaining pattern and histologic appearance of all tissue microarray slides were examined and scored by two independent pathologists. The intensity of nuclear and/or cytoplasmic immunostaining was scored on scale from 0 (no staining), 1 þ (week staining), 2 þ (moderate staining) to 3 þ (strongest staining), respectively.
Quantitative real-time PCR RNA was extracted from macrodissected primary tumor tissues or cultured cells homogenized in Trizol Reagent according to the manufacturer's instructions (Invitrogen). Superscript First-Strand Kit was used to synthesize first-strand cDNA (Invitrogen). Quantitative real-time PCR (qRT-PCR) was carried out with ABI Prism 7500 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) using primers: forward, 5 0 -ACTGATGCAGCAGACCTTTG-3 0 ; reverse, 5 0 -TGGCACTTGGTAGATGGTGT-3 0 ; and probe, 5 0 -6 FAM-TGCCAAACCCACAGGCTGCT-3 0 BAQ1 (Genscript Inc, Piscataway, NJ, USA). Quantitation of gene expression of HEF1 was calculated by the comparative Ct method (Aarskog and Vedeler, 2000) .
shRNA-mediated knockdown of HEF1 and b-catenin expression Lentiviral-based shRNA constructs against human HEF1 were provided by M Kim and L Chin (Harvard Medical School) . MISSION shRNA Lentiviral constructs targeting human b-catenin were packaged for transduction according to the manufacturer's instructions (Sigma). pLKO.1 empty vector (Sigma) was used as control shRNA. Thirty-six hours after transfection, the medium was harvested and spun down at 5000 r.p.m. for 10 min at 4 1C; the viral supernatants were then incubated with target cells in the presence of 8 mg/ml polybrene (Sigma). Knockdown efficiency was determined by western blot.
Chromatin immunoprecipitation assay
ChIP assays were conducted essentially as described by Spencer et al. (2003) . Primers for the native human Survivin promoter have been previously described (Ma et al., 2005) . 
HEF1 promoter constructs and mutagenesis
The HEF1 promoter fragment (À2011, þ 72) was PCR amplified from DNA sample isolated from HeLa cells using primers: forward, 5 0 -GATCCTCGAGCCTGATTCCAACA CCCTTGTGC-3 0 and reverse, 5 0 -GATCAAGCTTGCAG CGCTAGATGAAAGCGAGA-3 0 , and then cloned into the pGL3 Basic Luciferase reporter vector (Promega, Madison, WI, USA). Four consensus TCF/LEF-binding sites in HEF1 promoter construct were mutated as described (Kim et al., 2003) using Quickchange-XL Site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) following the manufacturer's protocol. The following primers were used to generate TCF site mutants: Site-1 mutant: forward, 5 0 -GACTCATCTTAC AGATGGGAAGGGATCTAACTCATTGTCCTCCTTTAT CCAGGTA-3 0 ; Site-2 mutant: forward, 5 0 -CAGAAGGAA AAACACTGCAGTGATAACATCTGGAGCTAGAAATG CCAGCCG-3 0 ; Site-3 mutant: forward, 5-AGCTCCTTGCA GACTGACATCGCAAAGTAATCTAACCGTTGAAAAG AACAAAAAAAGCAAAC-3 0 ; and Site-4 mutant: forward, 5 0 -TCATGTAGAGATTGTGAGGTGAATGGATCTAACAC GAAATGGGTTTATGAAGGAGTTGC-3 0 . All wild type and mutant promoter constructs were confirmed by direct sequencing.
Dual luciferase assay HEK293 cells were transfected with Firefly luciferase reporter constructs, control Renilla luciferase reporter pRL-TK, DVL2 (dishevelled 2, homologous to Drosophila dsh, a positive regulator of Wnt signaling), and b-catenin expression constructs using FuGENE HD transfection reagent (Roche, Indianapolis, IN, USA). Twenty-four hours post-transfection, cells were lysed with passive lysis buffer supplied in the dualluciferase reporter assay kit (Promega), and luciferase activity was then measured according to the manufacture's instruction.
Expression of exogenous proteins
The full-length HEF1 cDNA was expressed from the pCMVtag2A (Stratagene) or pEGFP-C1 (Clontech, Mountain View, CA, USA) expression vectors, and correct sequence was confirmed. The pcDNA3.1 plasmids encoding active form of b-catenin or mouse Dvl2 were kindly provided by E Fearon and T Dale (University of Michigan Medical School, Ann Arbor, MI, USA, and Cardiff University, Wales, UK). FuGENE 6 (Roche) was used for transfection. Protein expression was typically analyzed 24 h after transfection.
Cell proliferation and soft agar assays Cells were plated at a density of 10 5 cells/well in six-well plates. Cells were trypsinized at days 3, 6, and 9 and counted using a hemocytometer stained with trypan blue. Three independent experiments were done and each experiment was performed in triplicates. Clonogenic growth of cells was evaluated by assessing plating efficiency for anchorage-independent growth in soft agar using an approach described previously (Leone et al., 1993) . Colonies were scored at day 16 after plating.
Xenograft tumor growth assay Four-to six-week-old athymic nude (nu/nu) mice were purchased from NCI (Frederick, MD, USA) and housed in specific pathogen-free environment. SW480 cells infected with lentivirus containing shRNA for HEF1 or pLKO.1 vector control were harvested with a minimum amount of trypsin-EDTA (Ethylenediaminetetraacetic acid) and washed HEF1 promotes colorectal tumorigenesis and progression Y Li et al at least twice with PBS. Cells were counted and suspended in sterile PBS at a concentration of 2.0 Â 10 7 cells/ml. In all, 100 ml of the cell suspension were inoculated s.c. in the left (vector control) and right (shHEF1) flank. Mice were monitored thrice a week for tumor formation and illness. Tumor size was measured using a caliper weekly for 5 weeks. Five weeks after inoculation, mice were euthanized in keeping with the policy of the humane treatment of tumor-bearing animals. The tumors were then removed, and fixed for further histopathological examination.
in vitro migration and invasion assays Transwell membranes (8.0 mm pore inserts in 24-well BioCoat Chambers from BD Biosciences) were used to study cell migration and invasion in vitro. Cells were trypsinized, washed in PBS, and resuspended in serum-free media with 5 Â 10 4 cells per well in the upper chamber and Dulbecco's modified Eagles medium with 10% fetal bovine serum in the lower chamber. After 16-24 h of incubation, cells on the upper surface were removed by scrubbing with a cotton swab; filters were then stained with Diff-Quik Stain Set (Dade Behring, Newark, DE, USA). Three independent Â 20 fields for each well were used for quantitation.
Data analysis
All data are presented as mean ± s.e. of at least three independent experiments performed in triplicates. Statistical significance was determined by two-tailed Student's t-test. A P-value o0.05 was considered statistically significant.
